Reversal of Direct Oral Anticoagulants
Introduction to Reversal Agents
- Prothrombin Complex Concentrates (PCCs) are recommended as a non-specific reversal agent for direct oral anticoagulants (DOACs) when specific antidotes are unavailable, particularly for factor Xa inhibitors in life-threatening bleeding situations 1
- The American College of Cardiology recommends considering PCCs in scenarios such as life-threatening bleeding, bleeding in a critical organ or closed space, urgent or emergency surgery, and when specific antidotes are unavailable 1
Specific Reversal Agents
- Idarucizumab (Praxbind) is licensed specifically for dabigatran reversal and is a humanized monoclonal antibody fragment that binds dabigatran with 350-fold higher affinity than dabigatran has for thrombin 2
- Andexanet alfa is licensed for reversal of rivaroxaban and apixaban in major hemorrhage and is a specific reversal agent for factor Xa inhibitors 1
Prothrombin Complex Concentrates (PCCs)
- PCCs are available as 4-factor PCCs (containing factors II, VII, IX, X) and are not specifically licensed for DOAC reversal, but are used off-label for emergency reversal of factor Xa inhibitors 1, 4
- One randomized trial showed that non-activated 4-factor PCC reversed prolonged PT with rivaroxaban 3
- Clinical hemostasis was achieved in patients with major bleeding treated with 4-factor PCC, although the exact percentage is not provided in the relevant citation 3
Reversal Strategies
- For dabigatran-associated bleeding, the first choice is Idarucizumab (5g), and if unavailable, consider activated PCC (FEIBA), and consider hemodialysis if severe renal impairment 2, 4
- For factor Xa inhibitor-associated bleeding, the first choice is Andexanet alfa (if available), and if unavailable, consider 4-factor PCC, and consider activated charcoal if last dose taken within 3 hours 1, 3
- For all DOAC-associated bleeding, standard hemodynamic support measures, temporary cessation of DOACs, and consideration of resumption of anticoagulation after hemostasis is achieved are recommended, although the exact citation for this is not provided
Contraindications and Monitoring
- PCCs should not be used for elective surgery, gastrointestinal bleeds manageable with local measures, high DOAC levels without bleeding, or procedures that can be delayed for drug clearance 1
- Conventional coagulation tests (PT/INR, aPTT) have limited utility for monitoring DOAC effect, and calibrated chromogenic anti-FXa assays are preferred for factor Xa inhibitors, while diluted thrombin time or ecarin clot time using dabigatran calibrators are preferred for dabigatran 1